Bayer signs supply contract for electricity from renewable energy sources with Wuppertaler Stadtwerke
Milestone in reducing the CO2 footprint:
Contract secures electricity from 100 percent renewable energy sources for several Bayer sites - 120 GWh per year
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
Not intended for UK Media
AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms / AskBio is currently enrolling patients in the Phase II GenePHIT trial of AB-1002 for …
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
Not intended for UK Media
AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no attributed serious adverse events in all 11 patients at 18 months, meeting the primary objective / Based on …
Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company / Co-Founder and former Chief Scientific Officer R. Jude Samulski to remain member of AskBio Board of Directors
Bayer and Google Cloud to accelerate development of AI-powered healthcare applications for radiologists
Not intended for U.S. Media
New Bayer innovation platform will help organizations build AI-powered apps that assist radiologists, reducing burnout and supporting more efficient diagnoses
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting
Not intended for U.S. and UK Media
In New Drugs on the Horizon session, Bayer will present preclinical and clinical imaging data on actinium-225 (225Ac)-PSMA-Trillium, a targeted radionuclide therapy being developed for the treatment of metastatic castration resistant prostate …
Bayer Pharmaceuticals advances next generation of blockbuster medicines
Not intended for U.S. and UK Media
Latest data for elinzanetant clear the path to submission for regulatory approval / Acquisition of exclusive European commercialization rights for acoramidis strengthens cardiovascular portfolio / Prostate cancer drug Nubeqa™ (darolutamide) on …
Bayer’s European Carbon Initiative enables farmers, food processors and retailers to achieve carbon commitments and implement regenerative agriculture practices. By 2025, Bayer expects to significantly increase the number of food and ag value …
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
Not intended for UK Media
Development of next-generation sequencing companion diagnostics (CDx) / Goal is to help increase patient access to Bayer’s precision cancer therapies by offering decentralized genomic testing and rapid turnaround time
Bayer Pharmaceuticals streamlines Leadership Team for next phase of growth
Not intended for UK Media
Sebastian Guth to become Chief Operating Officer (COO) / Christine Roth to lead Global Commercialization organization
Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant
Not intended for UK Media
OASIS 3 study provides additional supporting efficacy data as well as long-term safety data of elinzanetant, complementing positive topline results of OASIS 1 and 2 studies / Bayer will submit data from OASIS 1, 2 and 3 studies to health …